U.S. markets open in 2 hours 29 minutes
  • S&P Futures

    3,437.25
    +5.00 (+0.15%)
     
  • Dow Futures

    28,196.00
    +14.00 (+0.05%)
     
  • Nasdaq Futures

    11,687.00
    +26.25 (+0.23%)
     
  • Russell 2000 Futures

    1,616.50
    +1.70 (+0.11%)
     
  • Crude Oil

    41.06
    -0.64 (-1.53%)
     
  • Gold

    1,922.40
    +7.00 (+0.37%)
     
  • Silver

    25.19
    +0.21 (+0.84%)
     
  • EUR/USD

    1.1862
    +0.0034 (+0.28%)
     
  • 10-Yr Bond

    0.7970
    0.0000 (0.00%)
     
  • Vix

    29.90
    +0.72 (+2.47%)
     
  • GBP/USD

    1.3069
    +0.0122 (+0.94%)
     
  • USD/JPY

    104.8230
    -0.6470 (-0.61%)
     
  • BTC-USD

    12,231.14
    +1,174.13 (+10.62%)
     
  • CMC Crypto 200

    245.85
    +6.93 (+2.90%)
     
  • FTSE 100

    5,824.47
    -64.75 (-1.10%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

What Kind Of Investors Own Most Of Imricor Medical Systems, Inc. (ASX:IMR)?

Simply Wall St
·5 mins read

The big shareholder groups in Imricor Medical Systems, Inc. (ASX:IMR) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

With a market capitalization of AU$183m, Imricor Medical Systems is a small cap stock, so it might not be well known by many institutional investors. Taking a look at our data on the ownership groups (below), it's seems that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about Imricor Medical Systems.

Check out our latest analysis for Imricor Medical Systems

ASX:IMR Ownership Breakdown July 8th 2020
ASX:IMR Ownership Breakdown July 8th 2020

What Does The Institutional Ownership Tell Us About Imricor Medical Systems?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

As you can see, institutional investors have a fair amount of stake in Imricor Medical Systems. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Imricor Medical Systems's historic earnings and revenue, below, but keep in mind there's always more to the story.

ASX:IMR Earnings and Revenue Growth July 8th 2020
ASX:IMR Earnings and Revenue Growth July 8th 2020

Our data indicates that hedge funds own 5.6% of Imricor Medical Systems. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Warren Herreid is currently the company's largest shareholder with 11% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.5% and 5.6%, of the shares outstanding, respectively. Additionally, the company's CEO Steve Wedan directly holds 3.9% of the total shares outstanding.

A closer look at our ownership figures suggests that the top 23 shareholders have a combined ownership of 50% implying that no one share holder has a majority.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of Imricor Medical Systems

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

It seems insiders own a significant proportion of Imricor Medical Systems, Inc.. It has a market capitalization of just AU$183m, and insiders have AU$46m worth of shares in their own names. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

General Public Ownership

The general public holds a 50% stake in IMR. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Company Ownership

We can see that Private Companies own 4.1%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Public Company Ownership

It appears to us that public companies own 7.5% of IMR. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Imricor Medical Systems (of which 1 is a bit unpleasant!) you should know about.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.